Programa de Pós-Graduação em Bioquímica e Bioprospecção (PPGBBio), Laboratório de Bioquímica e Neurofarmacologia Molecular (LABIONEM), Grupo de Pesquisa em Neurobiotecnologia (GPN), Centro de Ciências Químicas, Farmacêuticas e de Alimentos (CCQFA), Universidade Federal de Pelotas (UFPel), RS, CEP 96010-900, Pelotas, Brazil.
Instituto de Química Universidade Federal de Goiás (UFG), Goiânia Goiás, CEP 74690-900, Brazil.
Naunyn Schmiedebergs Arch Pharmacol. 2023 Nov;396(11):3033-3044. doi: 10.1007/s00210-023-02508-3. Epub 2023 May 9.
Depression is a multifactorial and heterogeneous disease with several neurobiological mechanisms underlying its pathophysiology, including dysfunctional glutamatergic neurotransmission, which makes the exploration of the glutamate pathway an interesting strategy for developing novel rapid-acting antidepressant treatments. In the present study, we aimed to evaluate the possible glutamatergic pathway relation in the antidepressant-like action of 2-phenyl-3-(phenylselanyl)benzofuran (SeBZF1) in Swiss mice employing the tail suspension test (TST). Male Swiss mice received drugs targeting glutamate receptors before acute SeBZF1 administration at effective (50 mg/kg) or subeffective (1 mg/kg) doses by intragastric route (ig). TST and the open-field test (OFT) were employed in all behavioral experiments. The pretreatment of mice with N-methyl-D-aspartate (NMDA) (0.1 pmol/site, intracerebroventricular, icv, a selective agonist of the NMDA receptors), D-serine (30 µg/site, icv, a co-agonist at the NMDA receptor), arcaine (1 mg/kg, intraperitoneal, ip, an antagonist of the polyamine-binding site at the NMDA receptor), and 6,7-dinitroquinoxaline-2,3-dione (DNQX) (2,5 µg/site, icv, an antagonist of the AMPA/kainate type of glutamate receptors) inhibited the antidepressant-like effects of SeBZF1 (50 mg/kg, ig) in the TST. Coadministration of a subeffective dose of SeBZF1 with low doses of MK-801 (0.001 mg/kg, ip, a non-competitive NMDA receptor antagonist) or ketamine (0.1 mg/kg, ip, a non-selective antagonist of the NMDA receptors) produced significant antidepressant-like effects (synergistic action). These findings suggest the involvement of the glutamatergic system, probably through modulation of ionotropic glutamate receptors, in the antidepressant-like action of SeBZF1 in mice and contribute to a better understanding of the mechanisms underlying its pharmacological effects.
抑郁症是一种多因素和异质性疾病,其病理生理学有多种神经生物学机制,包括谷氨酸能神经传递功能障碍,这使得探索谷氨酸途径成为开发新型快速抗抑郁治疗方法的一个有趣策略。在本研究中,我们旨在通过使用悬尾试验(TST)评估 2-苯基-3-(苯基硒基)苯并呋喃(SeBZF1)在瑞士小鼠中的抗抑郁样作用的可能谷氨酸能途径关系。雄性瑞士小鼠在通过灌胃(ig)给予有效(50mg/kg)或亚有效(1mg/kg)剂量的 SeBZF1 之前,接受靶向谷氨酸受体的药物处理。所有行为实验均采用 TST 和旷场试验(OFT)。用 N-甲基-D-天冬氨酸(NMDA)(0.1pmol/site,侧脑室,icv,NMDA 受体的选择性激动剂)、D-丝氨酸(30μg/site,icv,NMDA 受体的共激动剂)、arcaine(1mg/kg,腹腔内,ip,NMDA 受体多胺结合部位的拮抗剂)和 6,7-二硝基喹喔啉-2,3-二酮(DNQX)(2,5μg/site,icv,AMPA/ kainate 型谷氨酸受体的拮抗剂)预处理小鼠,可抑制 SeBZF1(50mg/kg,ig)在 TST 中的抗抑郁样作用。亚有效剂量的 SeBZF1 与低剂量的 MK-801(0.001mg/kg,ip,NMDA 受体非竞争性拮抗剂)或氯胺酮(0.1mg/kg,ip,NMDA 受体非选择性拮抗剂)联合给药可产生显著的抗抑郁样作用(协同作用)。这些发现表明,谷氨酸能系统可能通过调节离子型谷氨酸受体参与 SeBZF1 在小鼠中的抗抑郁样作用,并有助于更好地理解其药理作用的机制。